Leading pharmaceutical companies frequently "cut meat" because three major imitations and category 1 new drugs will impact the market

Pharmaceutical Network June 17th, June 15th, Tianshili announced that it intends to sell Tianshi Marketing for no more than 1,489 million yuan, divest it of commercial assets of pharmaceuticals, focus on the advantages of resources focused on the pharmaceutical industry; In the past year, affected by the national collection, generic drugs are frequently reducing prices, new drug research and development has become a new way out for pharmaceutical companiesTianshili sold its wholesale leader for $1.5 billion and Beida's $250 million transfer technology companyTable 1: 2019 Tianshi Marketing Performance (unit: 10,000 yuan)Source: Company Announcement
According to TianshiLi Major Asset Sale Report (Draft) Data show that Tianshi Marketing is a controlling subsidiary of listed companies, the main business is third-party pharmaceutical industrial enterprises pharmaceutical, Distribution and distribution of medical devices, health care products and other products, in 2019 Tianshi marketing operating income of 13.4 billion yuan, accounting for 70.71 percent of the total revenue of listed companies, total assets of 9.17 billion yuan, accounting for 38.20% of the total assets of listed companiesTianshi Marketing was listed on the new three boards from August 15, 2017 to January 3, 2020, and has been known as the "New Three Boards and One Brother", ranking 20th in the national pharmaceutical wholesale main business revenue in 2019Tian Shili said that through the sale of this asset, focus on the advantages of resources to focus on the pharmaceutical industry, continue to promote the coordinated development of modern Chinese medicine, biological drugs and chemical drugs, and build an innovative pharmaceutical research and development clusterAt the same time, the company through the sale of Tianshi marketing assets will effectively reduce the ratio of assets and liabilities, improve the company's operating cash flow, improve shareholder return on investment, and further improve the quality of operations and operational efficiencyThe shares of heavy pharmaceutical stake of the heavy drug holding subsidiary of "Takeover Man" will be no higher than 9.41 yuan per share, and the acquisition of Tianshi Marketing shall not be less than 158 million shares, the total share price shall not exceed 1.489 billion yuan, and Tianshi Marketing will consolidate the statement after the completion of the acquisitionIn the future, the main business of heavy pharmaceutical shares will be added 5 blank provinces and municipalities directly under the Central Government coverage, in the national pharmaceutical wholesale enterprise ranking is expected to enter the top sixOn June 15, Beida Pharmaceuticals announced the sale of the wholly-owned subsidiary's equity and related transactions, to sell to Ningbo Keming Innovation Technology Co., Ltdthe entire stake in Zhejiang Beda Pharmaceutical Technology Co., Ltd., the transaction value of 251 million yuanBeida Pharmaceuticals said that the main project of the target company is the construction of the hatching base of Haichengyuan, has been completed, as a listed company based on innovative drugs, the company's research and development investment in large, long cash cycle, through the sale of the target company's equity, can achieve the rapid return of funds to support the development of innovative drugs business, in order to enhance the company's core competitivenessTianshili's research and development investment of more than 800 million, 3 first imitation is worth looking forward to
According to Tianshili annual report data show that in 2019 the company invested 810 million yuan in research and development, accounting for 4.26% of the company's operating income, accounting for 13.03% of the pharmaceutical industry revenueTable 2: 2019 to today Shili approved productsSource: MED China Drug Review Database 2.0
according to Minnet data, 2019, A total of 6 products of Tianshili were successfully approved, of which hemp antispasm particles became the only approved pediatric chinese medicine in the last five yearsHemp antispasm particles for the company's exclusive varieties, indications for Tourette syndrome (pumping-filth syndrome) and chronic extraction disorder, with the effect of calming the liver and yang, the air to stop spasms, clear the fire sputumHe Darafei film 4 types of imitation approved and treated as the same, so far has been rated up to 6 enterprisesIn 2019, TOP20, a drug product for chemical urology systems in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as public medical institutions in China), ranked sixth in the tadalafi a piece with sales of more than 130 million yuanIn the second batch of national collection stage, Tianshi LiYi Pharmaceuticals and Changchun Haiyue Pharmaceuticals won the bid, Tianshili won Beijing, Tianjin and other 16 cities, is expected to usher in 2020 will usher in the releaseIn terms of consistency evaluation, the demomine capsule, the right zopicyclon tablet, the pyrapamine tablets, the hydrochloric acid benzene seaso tablets have been evaluated, together with the tadalafi film, as of now, Tianshili has reviewed or treated as a review of the product has 5The pyrethroid capsule is a heavy product of Tianshili, in 2019 in China's public medical institutions terminal sales broke 1.3 billion yuan, currently only Tianshili a review;Table 3: 2019-today Shili's pending listing application and consistency evaluationSource: MED China Drug Review Database 2.0
2019, TianshiLi's pending listing application involves 5 products, of which left Shubili tablets, benzozabet slow release tablets, hydrochloric acid Mei-King Kong release capsules are expected to win the first imitation Left Shubili tablets are currently only Tianshili declared imitation and in the review; Shaanxi step-high-tech pharmaceutical Benzene-Benzene slow release tablet 6 imitation was approved in 2016 after the clinical no latest news, there is no other enterprise acceptance number in the review;In addition, injection of pyridine currently only Hengrui in 2019 to obtain production approval, after the listing of sales all the way up, the current Sichuan Huiyu Pharmaceutical, Osekang Pharmaceuticals, Tianshili 3 types of generic listing applications are in the review and approval, finally who can follow Hengrui after the listing, we wait and seeShubili film sales in 2019 is about 68 million yuan, leading enterprise Enhua Pharmaceuticals market share of more than 50%, Tianshili ranked second, market share in about 11%, the product is currently no enterprise evaluation, only Tianshili's consistency evaluation supplementary application in the review and approval, won the first review of the day to be 　　Beida Pharmaceuticals research and development investment accounted for more than 40% of revenue, 1 class of new drug Enshatinib listed in the Beida Pharmaceuticals is a typical innovative pharmaceutical company, the company's main product selling for the 2011 independent research and development of 1.1 new drug Etryni, as of the end of 2019, the cumulative sales of the product exceeded 7 billion yuan The company's overall performance growth has slowed after Ektini entered the health-care trade-in, especially after the company's performance has been under pressure In recent years, the company adhered to new drug research and development, through independent research and development and strategic cooperation, gradually enriched the company's research and development pipeline, in 2019 the company's research and development investment reached 675 million yuan, accounting for 43.41 percent of operating income, an increase of 14.33 percent over the same period in 2018 　　Class 1 new drug nsatinib nsatini capsules are listed on the market, for patients with local lysatary lymphoma kinase (ALK) positive for progress after previous treatment of coctinininin, or who are not tolerated to coctininib, and are currently in the CDE review stage, have submitted supplementation data and been approved for listing into the countdown 　　Table 4: Beida Pharmaceuticals 2019-present Clinical Lymics 1 New Drug Source: MED China Drug Review Database 2.0 BPI-28592 is a new type of strong, highly selective promymidocyplobin receptor kinase (TRK) (also known as neurotrophic tyrosine tyrosine kinase (NTRK) second-generation oral small molecular inhibitors that can cover a wide range of cancers, and are intended to carry NT It is reported that only two TRK inhibitors in the world to commercialize, of which Larotrectinib (Larotinib) is listed in the United States, Entrectinib (Entrectinib) is listed in the United States and Japan, and there are no TRK inhibitors on the Chinese market 　　BPI-27336 tablets are a new type of powerful, selective extracellular regulatory kinase 1/2 (ERK1/2) oral small molecule inhibitors for RAS/RAF/MEK-activated mutation of colorectal cancer, pancreatic cancer, lung cancer, liver cancer, stomach cancer, melanoma and other solid tumor treatment, there is no global listed ERK1/2 inhibitor 　　BPI-23314 tablets are a powerful, highly selective bromine domain and end-of-end extraterritorial (BET) oral small molecular inhibitors, which can regulate the transcription of cancer-related genes by specifically inhibiting the function of BET family protein, and then affect cell growth, proliferation, apoptosis and other physiological processes, and finally reach tumor inhibition growth, approved single drug for malignant blood system tumors (acute myeloid leukemia, non-Hodgkina 　　On June 15, Beida Pharmaceuticals announced that the application for listing of Beval-Zhusing single injection (MIL60) was accepted by CDE Minnet data show that the current domestic market has Roche approved imports, Qilu Pharmaceuticals in December 2019 approved production, Shandong Green Leaf Pharmaceuticals, Suzhou Shengdia Biopharmaceuticals (Hengrui subsidiary), Cinda Biopharma's listing application is being reviewed and approved 　　Conclusion
In recent years, the new policy of medical reform has emerged, and the pharmaceutical industry has suffered a major reshuffle Tianshili as a traditional Chinese medicine enterprises, but also to biological drugs, chemical drugs and cooperative development of the road transformation, the most burning of the road of innovation, this time 1.5 billion sold Tianshi marketing, it can be seen that it for innovation under the heavy book Beida Pharmaceuticals to innovative drugs to make a name for it, in recent years there are many new drugs approved clinically, to resolve the risk of a single product, only to continue to promote research and development, accelerate product market Recently, Xinbang Pharmaceuticals also want to sell two subsidiaries, the total amount of equity transfer of 750 million, the purpose is also to focus on the main industry, it can be foreseen that similar "cut meat" events will continue to occur, however, for the pharmaceutical industry will be the necessary choice to extract refinement Source: Company Announcement, MnetDatabase
review data as of 16 June 2020